CN105596890A - 一种制备治疗肺癌的中药组合物的方法 - Google Patents
一种制备治疗肺癌的中药组合物的方法 Download PDFInfo
- Publication number
- CN105596890A CN105596890A CN201610042686.XA CN201610042686A CN105596890A CN 105596890 A CN105596890 A CN 105596890A CN 201610042686 A CN201610042686 A CN 201610042686A CN 105596890 A CN105596890 A CN 105596890A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- lung cancer
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 39
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 39
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims abstract description 19
- 241000660877 Coridius Species 0.000 claims abstract description 20
- 241000218176 Corydalis Species 0.000 claims abstract description 20
- 210000000582 semen Anatomy 0.000 claims abstract description 20
- 240000002948 Ophiopogon intermedius Species 0.000 claims abstract description 18
- 241001116477 Adenophora triphylla Species 0.000 claims abstract description 13
- 238000001035 drying Methods 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 238000000605 extraction Methods 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract 5
- 239000000843 powder Substances 0.000 claims description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 241000031023 Amana edulis Species 0.000 claims description 20
- 241000255789 Bombyx mori Species 0.000 claims description 19
- 244000077995 Coix lacryma jobi Species 0.000 claims description 19
- 241000244987 Daiswa polyphylla Species 0.000 claims description 19
- 239000000706 filtrate Substances 0.000 claims description 12
- 241001412627 Adenophora liliifolia Species 0.000 claims description 11
- 230000006837 decompression Effects 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- 241000867477 Amara Species 0.000 claims description 8
- 238000004064 recycling Methods 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 210000004072 lung Anatomy 0.000 abstract description 24
- 208000002193 Pain Diseases 0.000 abstract description 10
- 239000000463 material Substances 0.000 abstract description 10
- 208000024891 symptom Diseases 0.000 abstract description 9
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 208000037819 metastatic cancer Diseases 0.000 abstract description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 abstract description 3
- 230000002980 postoperative effect Effects 0.000 abstract description 3
- 230000001502 supplementing effect Effects 0.000 abstract description 3
- 244000018633 Prunus armeniaca Species 0.000 abstract description 2
- 235000009827 Prunus armeniaca Nutrition 0.000 abstract description 2
- 230000036528 appetite Effects 0.000 abstract description 2
- 235000019789 appetite Nutrition 0.000 abstract description 2
- 241000255791 Bombyx Species 0.000 abstract 1
- 241001250596 Pleione Species 0.000 abstract 1
- 241000756042 Polygonatum Species 0.000 abstract 1
- 235000008737 Polygonatum biflorum Nutrition 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000005904 anticancer immunity Effects 0.000 abstract 1
- 238000009792 diffusion process Methods 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 238000000227 grinding Methods 0.000 abstract 1
- 238000013508 migration Methods 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 238000005303 weighing Methods 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 25
- 201000011510 cancer Diseases 0.000 description 18
- 206010011224 Cough Diseases 0.000 description 14
- 206010062717 Increased upper airway secretion Diseases 0.000 description 9
- 208000026435 phlegm Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 206010007247 Carbuncle Diseases 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 206010036790 Productive cough Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 206010013789 Dry throat Diseases 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000017574 dry cough Diseases 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000037111 immune power Effects 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/342—Adenophora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Insects & Arthropods (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于中药技术领域,涉及一种制备治疗肺癌的中药组合物的方法,该方法为称取以下原料:苦杏仁、僵蚕、沙参、麦门冬、玉竹、九香虫、重楼、苦参、山慈菇、薏苡仁和延胡索,将原料分别处理,经粉碎、提取、过滤、浓缩、干燥等工序制得中药组合物。本发明制剂工艺简单,制备的中药组合物仅由11味常见中药材组成,无奇缺,药材共用可相互协同,既可以起到益气养阴、扶正固本,清热解毒,活血化淤,软坚散结的功效,又可提高人体自身抗癌免疫力,重新平衡患者体内阴阳,有效控制肺癌细胞的复制、扩散和转移,同时可改善患者疼痛、身体乏力及食欲不振等症状,可用于肺癌术后、中晚期肺癌、肺部转移癌的治疗以及延长患者的生存期。
Description
技术领域
本发明属于中药技术领域,具体涉及一种制备治疗肺癌的中药组合物的方法。
背景技术
由于环境污染,生活环境及生活习惯的变迁,恶性肿瘤即癌症的发病率越来越高。恶性肿瘤也就是人们所熟悉的癌症,如乳腺癌、肺癌、胃癌、脂肪肉瘤等。另外,有些虽然没有称为癌,但也属于恶性肿瘤范畴,如白血病、恶性淋巴瘤等。恶性肿瘤有早期不易发现、生长速度快、生长不受限制、对本身及周围组织器官的破坏性大、手术切除后易于复发和转移等特点,因此疗效及预后差,致使人们常常对癌症存在很多错误认识,甚至极度恐癌,谈癌色变。其实跟心脑血管疾病一样,癌症也是一种慢性病,可防可治,早诊早治意义重大。
从全国的统计数据来看,肺癌是第一大致死癌症。对人群健康和生命威胁最大的恶性肿瘤之一。肺癌”是目前世界公认的“癌中之王”,据国际癌症研究机构最新数据显示,全球2010年因肺癌死亡的患者中,22.3万人因大气污染患癌。全国肿瘤登记中心发布的《2012中国肿瘤登记年报》显示,我国每年新发肿瘤病例约为312万例,平均每天8,550人,全国每分钟有6人被诊断为癌症,而恶性肿瘤发病第一位的是肺癌。过去30年间,我国肺癌死亡率上升了465%,成为上升速度最快的癌症,并且已取代肝癌成为我国首位肿瘤死因。
中药的辅助抗癌的作用,近年来越来越受到重视,尤其是作为晚期保守治疗的药物,其重要性是不言而喻的。
发明内容
本发明目的是提供一种制备治疗肺癌的中药组合物的方法,该方法制备的中药组合物调节人体阴阳平衡,以及增强机体抗癌能力,可明显延长肺癌患者生存期。
本发明治疗肺癌的中药组合物采用以下组分制备而成:苦杏仁、僵蚕、沙参、麦门冬、玉竹、九香虫、重楼、苦参、山慈菇、薏苡仁和延胡索。
优选的,所述的沙参为南沙参。
优选的,本发明中药组合物重量份如下:苦杏仁100-300份、僵蚕100-300份、南沙参50-200份、麦门冬200-400份、玉竹50-200份、九香虫50-200份、重楼100-300份、苦参50-200份、山慈菇200-400份、薏苡仁100-300份、延胡索50-200份。
优选的,本发明中药组合物重量份如下:苦杏仁180份、僵蚕240份、南沙参100份、麦门冬320份、玉竹160份、九香虫60份、重楼120份、苦参160份、山慈菇260份、薏苡仁160份、延胡索120份。
优选的,本发明中药组合物重量份如下:苦杏仁200份、僵蚕200份、南沙参100份、麦门冬280份、玉竹120份、九香虫120份、重楼200份、苦参120份、山慈菇300份、薏苡仁200份、延胡索200份。
方中:
苦杏仁归肺、大肠经。主治止咳平喘,润肠通便。主要用于咳嗽气喘,肠燥便秘等。僵蚕味咸,能够软坚散结,又兼可化痰,故能治疗痰核、瘰疬、疮疡肿毒等。僵蚕醇提取物对小鼠艾氏腹水癌实体型肉瘤S180有抑制作用,体外可抑制肝癌细胞呼吸。南沙参味甘性微寒,为清热养阴生津之佳品。入肺经,能清肺热,养肺阴,用于热伤肺阴所致的干咳痰少、咽干口渴之证,又可用于风温燥邪侵袭肺卫,灼伤肺阴所致的咳嗽少痰,咽干口渴之证。枟本草纲目枠云其“清肺火,治久咳肺痿”,故亦可用于阴虚劳热咳嗽咯血。南沙参长于养阴清肺;麦门冬善于养阴润肺。两药配伍,可增强清肺热,养肺阴的作用。适用于热伤肺阴所致的干咳痰少、咽干口渴之证。杏叶沙参煎剂可提高细胞免疫和非特异性免疫,且可抑制体液免疫,具有调节免疫平衡的功效。麦门冬养阴清热,归于肺,故可用于肺痈初起,气阴两虚,咳嗽气喘,胸中隐痛,呕吐脓痰;养阴润肺,益胃生津。玉竹主要用于燥热咳嗽,津伤口渴,阴虚外感,头痛身热等。玉竹甘寒质润,长于滋肺阴,润肺燥,常用于燥热伤肺,干咳少痰,舌红少津之证。玉竹又可清肺化痰,润肺止咳,故又可用于肺经邪热炽盛,伤及肺阴而致热痰咳嗽。玉竹的乙醇提取物是一种以增强体液免疫及吞噬免疫功能为主的免疫增强剂。九香虫味咸性温,能温通利膈而有行气止痛之功。适用于肝气郁滞之胸胁胀痛或肝胃不和之胃脘疼痛。重楼(蚤休)苦以降泄,寒能清热,故有清热解毒,消肿止痛之功,为治痈肿疔毒、毒蛇咬伤的要药。重楼对小鼠肉瘤S180、肉瘤S37、实体型肝癌有抑制作用。苦参大苦大寒,纯阴纯降,其功似黄连,善于清热燥湿,为治湿热内蕴之常用药。苦参既可清热燥湿,又能清热利尿,导湿热外出,有良好的除湿热退黄作用,亦可用于湿热黄疸、带下赤白。苦参及其提取物对路易斯肺癌、S180实体瘤、艾氏癌实体型等具有不同程度的抗癌作用。山慈菇味辛能散,寒能清热,故有清热解毒、消痈散结之效,可用治痈疽发背、疔疮恶肿,内服外用均可。山慈菇有解毒散结消肿之功,近年来广泛用于癥瘕痞块和多种肿瘤。薏苡仁能健脾益胃,入肺经,有虚则补其母之义,兼能清热排脓,为治疗内痈的要药,故肺痿、肺痈咳唾脓痰,胸痛等以及肠痈,常用其清肺肠之热,排脓消痈。延胡索活血,行气,止痛。辛散苦降温通之性,既入血分,又入气分。既能行血中之气,又能行气中之血。能消瘀血,散滞气,止疼痛,为活血行气止痛之良药。以上11中药材配伍使用,可以相互协同,既可以起到益气养阴、扶正固本,清热解毒,活血化淤,软坚散结的功效,又可提高人体自身抗癌免疫力,重新平衡患者体内阴阳,有效控制肺癌细胞的复制、扩散和转移,可用于肺癌术后、中晚期肺癌、肺部转移癌的治疗以及延长患者的生存期。
本发明公开一种制备治疗肺癌的中药组合物的方法,具体地包括以下步骤:
1)取九香虫、僵蚕粉碎成细粉,备用;
2)将苦杏仁、重楼、苦参和沙参粉碎混匀加60-80%乙醇回流提取二次,每次1-2小时,滤过,滤液合并,药渣备用,减压回收乙醇,浓缩成相对密度为1.35(60℃)的稠膏,减压干燥,粉碎成细粉,备用;
3)将麦门冬、玉竹、山慈菇、薏苡仁和延胡索粉碎后与步骤2)的所得药渣混匀,加水回流提取两次,每次1-2小时,滤液合并,减压浓缩成相对密度为1.35(60℃)的稠膏,减压干燥,粉碎成细粉,备用;
4)将步骤1)、2)、3)所得细粉混匀,制备成药物制剂。
本发明的中药组合物还可以加一种或多种药学上可接受的药用辅料,制成常规口服制剂,如片剂、胶囊、口服液、颗粒、滴丸等,优选为胶囊剂。
本发明还公开上述中药组合物在制备治疗肺癌药物中的用途。
本发明具有以下显著性进步:
本发明中药组合物仅由11味常见中药材组成,无奇缺,药材共用可相互协同,既可以起到益气养阴、扶正固本,清热解毒,活血化淤,软坚散结的功效,又可提高人体自身抗癌免疫力,重新平衡患者体内阴阳,有效控制肺癌细胞的复制、扩散和转移,同时可改善患者疼痛、身体乏力及食欲不振等症状,可用于肺癌术后、中晚期肺癌、肺部转移癌的治疗以及延长患者的生存期。此外本发明治疗肺癌的中药组合物制剂工艺简单,服药剂量少,用药安全,无毒副作用。
具体实施方式
下面结合具体实施例,进一步阐述本发明。这些实施例应理解为仅用于说明本发明而不用于限制本发明的保护范围。在阅读了本发明记载的内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等效变化和修饰同样落入本发明权利要求所限定的范围。
实施例1:
处方:苦杏仁180份、僵蚕240份、南沙参100份、麦门冬320份、玉竹160份、九香虫60份、重楼120份、苦参160份、山慈菇260份、薏苡仁160份、延胡索120份。
制备方法:
1)取九香虫、僵蚕粉碎成细粉,备用;
2)将苦杏仁、重楼、苦参和沙参粉碎混匀加60%乙醇(体积比)回流提取二次,每次1小时,滤过,滤液合并,药渣备用,减压回收乙醇,浓缩成相对密度为1.35(60℃)的稠膏,减压干燥,粉碎成细粉,备用;
3)将麦门冬、玉竹、山慈菇、薏苡仁和延胡索粉碎后与步骤2)的所得药渣混匀,加水回流提取两次,每次1时,滤液合并,减压浓缩成相对密度为1.35(60℃)的稠膏,减压干燥,粉碎成细粉,备用;
4)将步骤1)、2)、3)所得细粉与适量辅料混匀,制成颗粒,装入胶囊,制成1000粒,即得。
实施例2:
处方:苦杏仁200份、僵蚕200份、南沙参100份、麦门冬280份、玉竹120份、九香虫120份、重楼200份、苦参120份、山慈菇300份、薏苡仁200份、延胡索200份。
制备方法:
1)取九香虫、僵蚕粉碎成细粉,备用;
2)将苦杏仁、重楼、苦参和沙参粉碎混匀加80%乙醇(体积比)回流提取二次,每次1.5小时,滤过,滤液合并,药渣备用,减压回收乙醇,浓缩成相对密度为1.35(60℃)的稠膏,减压干燥,粉碎成细粉,备用;
3)将麦门冬、玉竹、山慈菇、薏苡仁和延胡索粉碎后与步骤2)的所得药渣混匀,加水回流提取两次,每次1时,滤液合并,减压浓缩成相对密度为1.35(60℃)的稠膏,减压干燥,粉碎成细粉,备用;
4)将步骤1)、2)、3)所得细粉与适量辅料混匀,制成颗粒,装入胶囊,制成1000粒,即得。
实施例3:
处方:苦杏仁300份、僵蚕300份、南沙参200份、麦门冬400份、玉竹200份、九香虫200份、重楼300份、苦参200份、山慈菇400份、薏苡仁300份、延胡索200份。
制备方法:
1)取九香虫、僵蚕粉碎成细粉,备用;
2)将苦杏仁、重楼、苦参和沙参粉碎混匀加75%乙醇回流提取二次,每次1.5小时,滤过,滤液合并,药渣备用,减压回收乙醇,浓缩成相对密度为1.35(60℃)的稠膏,减压干燥,粉碎成细粉,备用;
3)将麦门冬、玉竹、山慈菇、薏苡仁和延胡索粉碎后与步骤2)的所得药渣混匀,加水回流提取两次,每次1.5时,滤液合并,减压浓缩成相对密度为1.35(60℃)的稠膏,减压干燥,粉碎成细粉,备用;
4)将步骤1)、2)、3)所得细粉与适量辅料混匀,制成颗粒,装入胶囊,制成2000粒,即得。
实施例4:
处方:苦杏仁300份、僵蚕200份、南沙参100份、麦门冬200份、玉竹100份、九香虫100份、重楼200份、苦参100份、山慈菇200份、薏苡仁200份、延胡索100份。
制备方法:
1)取九香虫、僵蚕粉碎成细粉,备用;
2)将苦杏仁、重楼、苦参和沙参粉碎混匀加70%乙醇回流提取二次,每次1小时,滤过,滤液合并,药渣备用,减压回收乙醇,浓缩成相对密度为1.35(60℃)的稠膏,减压干燥,粉碎成细粉,备用;
3)将麦门冬、玉竹、山慈菇、薏苡仁和延胡索粉碎后与步骤2)的所得药渣混匀,加水回流提取两次,每次1时,滤液合并,减压浓缩成相对密度为1.35(60℃)的稠膏,减压干燥,粉碎成细粉,备用;
4)将步骤1)、2)、3)所得细粉与适量辅料混匀,制成颗粒,装入胶囊,制成1000粒,即得。
实施例5:
处方:苦杏仁240份、僵蚕240份、南沙参120份、麦门冬360份、玉竹120份、九香虫120份、重楼240份、苦参120份、山慈菇360份、薏苡仁240份、延胡索120份。
制备方法:
1)取九香虫、僵蚕粉碎成细粉,备用;
2)将苦杏仁、重楼、苦参和沙参粉碎混匀加60%乙醇回流提取二次,每次1小时,滤过,滤液合并,药渣备用,减压回收乙醇,浓缩成相对密度为1.35(60℃)的稠膏,减压干燥,粉碎成细粉,备用;
3)将麦门冬、玉竹、山慈菇、薏苡仁和延胡索粉碎后与步骤2)的所得药渣混匀,加水回流提取两次,每次1时,滤液合并,减压浓缩成相对密度为1.35(60℃)的稠膏,减压干燥,粉碎成细粉,备用;
4)将步骤1)、2)、3)所得细粉与适量辅料混匀,制成颗粒,装入胶囊,制成1000粒,即得。
本发明治疗肺癌的中药组合物对移植性小鼠Lewis肺癌的影响
1.实验材料
1.1实验药物:本发明中药组合物(本发明实施例1、实施例2),环磷酰胺。
1.2实验动物:SPF级KM小鼠60只,4周龄,雌雄各半,体重20±5克,根据完全随机分组方法进行分组;随机分为4组:模型组、对照组、实验1组、实验2组。每组15只。
1.3实验瘤株:肺癌Lewis瘤株。
2.实验方法
小鼠肺癌Lewis瘤株细胞培养于1640培养液中,37℃,5%CO2下常规培养,平均每2天传代1次,至对数生长期时用生理盐水制备成密度为3.0×107个/ml单细胞悬液,在无菌条件下注射于小鼠腹腔内,接种后7天见小鼠腹腔明显肿大,此时,脱颈处死,放入盛有75%乙醇的烧杯中浸泡2-3分钟,将消毒后的小鼠放入超净工作台中,暴露腹部,用无菌注射器抽取腹水放入无菌试剂瓶内备用。将上述腹水用台盼蓝计数,用生理盐水稀释,调整细胞数至1.0×107个/ml,接种于小鼠右腋下,每只0.4ml。
小鼠接种肿瘤后第4天开始给药,每天上午给药一次,连续给药14天,各组给药方法如下:
模型组:灌胃等量的生理盐水;
对照组:环磷酰胺(20mg/kg/d),腹腔注射;
实验1组:实施例1中药(5g生药/kg/d),灌胃;
实验2组:实施例2中药(5g生药/kg/d),灌胃。
称体重,摘瘤,称重,计算抑瘤率,计算公式如下:
抑瘤率(%)=(1-给药组平均瘤重/模型组平均瘤重)×100%
3.统计学方法
数据采用SPSS19.0软件进行统计分析,计量资料以表示,治疗前后指标比较采用t检验;计数资料采用X2检验。P<0.05具有统计学意义。
4.实验结果
表1本发明中药组合物对小鼠肺癌瘤重和抑瘤率的影响()
备注:*表示与模型组比较P<0.05;
讨论:与模型组相比,本发明中药组合物可显著抑制肺癌Lewis实体瘤,作用强度同环磷酰胺对照组。
临床实验数据
1.病例选择及分组
肺癌早期可无任何症状,大多在胸部X线检查时发现,肿瘤增大后,常出现咳嗽、咳痰、痰中带血或少量咳血,继发感染可有脓性痰,并有发热、食欲减退、消瘦等。凡具有胸部X线检查时发现,肺部有肿块,并常出现咳嗽、咳痰、痰中带血或少量咳血,继发感染可有脓性痰,并有发热、食欲减退、消瘦症状者,均可诊断为肺癌。在实际操作中,可按照国家卫生部制订的中药新药治疗肺癌的临床研究指导原则确立中西医诊断标准和试验病例标准。
凡是选择符合上述肺癌诊断标准的患者均作为选择病例,共计114例,随机分为实验1组38例,实验2组38例,对照组38例,三组症状,病程,年龄、性别等,经统计学处理具有可对比性。
2.治疗方法
实验1组:在给予常规的西医治疗(氟尿嘧啶、长春新碱和环磷酰胺)的基础上,加服本发明实施例1方法制备的胶囊剂,每天3次,每次4粒,30天为一疗程,连续治疗6个疗程。
实验2组:在给予常规的西医治疗(氟尿嘧啶、长春新碱和环磷酰胺)的基础上,加服本发明实施例2方法制备的胶囊剂,每天3次,每次4粒,30天为一疗程,连续治疗6个疗程。
对照组:仅给予常规的西医治疗。
3.疗效标准
显效:症状完全缓解或消失,生存期达5年以上。
有效:症状部分缓解,生存期1年以上。
无效:症状无任何改善,有恶化之趋势,甚而短时间即死亡。
4.实验结果
表2治疗后生存期
实验结果提示服用本发明中药的患者5年生存率约为60.5%、57.9%,而对照组仅为15.8%。本发明实验组与对照组具有显著性差异。可见本发明中药组合物可以显著延长患者生存期。
Claims (6)
1.一种制备治疗肺癌的中药组合物的方法,包括以下步骤:
1)取九香虫、僵蚕粉碎成细粉,备用;
2)将苦杏仁、重楼、苦参和沙参粉碎混匀加60-80%乙醇回流提取二次,每次1-2小时,滤过,滤液合并,药渣备用,减压回收乙醇,浓缩成相对密度为1.35(60℃)的稠膏,减压干燥,粉碎成细粉,备用;
3)将麦门冬、玉竹、山慈菇、薏苡仁和延胡索粉碎后与步骤2)的所得药渣混匀,加水回流提取两次,每次1-2小时,滤液合并,减压浓缩成相对密度为1.35(60℃)的稠膏,减压干燥,粉碎成细粉,备用;
4)将步骤1)、2)、3)所得细粉混匀,制备成药物制剂。
2.如权利要求1所述的制备治疗肺癌的中药组合物的方法,其特征在于:所述的沙参为南沙参。
3.如权利要求2所述的制备治疗肺癌的中药组合物的方法,其特征在于,所述中药组合物由如下重量份的原料制成:苦杏仁100-300份、僵蚕100-300份、南沙参50-200份、麦门冬200-400份、玉竹50-200份、九香虫50-200份、重楼100-300份、苦参50-200份、山慈菇200-400份、薏苡仁100-300份、延胡索50-200份。
4.如权利要求3所述的制备治疗肺癌的中药组合物的方法,其特征在于,所述中药组合物由如下重量份的原料制成:苦杏仁180份、僵蚕240份、南沙参100份、麦门冬320份、玉竹160份、九香虫60份、重楼120份、苦参160份、山慈菇260份、薏苡仁160份、延胡索120份。
5.如权利要求1-4任一所述的制备治疗肺癌的中药组合物的方法,其特征在于:所述的中药组合物被制成口服制剂。
6.如权利要求5所述的制备治疗肺癌的中药组合物的方法,其特征在于:所述的口服制剂为片剂、胶囊、口服液、颗粒、滴丸。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610042686.XA CN105596890A (zh) | 2016-01-22 | 2016-01-22 | 一种制备治疗肺癌的中药组合物的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610042686.XA CN105596890A (zh) | 2016-01-22 | 2016-01-22 | 一种制备治疗肺癌的中药组合物的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105596890A true CN105596890A (zh) | 2016-05-25 |
Family
ID=55977607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610042686.XA Withdrawn CN105596890A (zh) | 2016-01-22 | 2016-01-22 | 一种制备治疗肺癌的中药组合物的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105596890A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105943945A (zh) * | 2016-06-18 | 2016-09-21 | 冯原 | 一种治疗肺癌的中药组合物、滴丸剂及其制备方法 |
CN106421380A (zh) * | 2016-09-23 | 2017-02-22 | 河南中医药大学 | 一种治疗肺鳞癌和小细胞肺癌的中药复合物 |
-
2016
- 2016-01-22 CN CN201610042686.XA patent/CN105596890A/zh not_active Withdrawn
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105943945A (zh) * | 2016-06-18 | 2016-09-21 | 冯原 | 一种治疗肺癌的中药组合物、滴丸剂及其制备方法 |
CN106421380A (zh) * | 2016-09-23 | 2017-02-22 | 河南中医药大学 | 一种治疗肺鳞癌和小细胞肺癌的中药复合物 |
CN106421380B (zh) * | 2016-09-23 | 2019-10-15 | 河南中医药大学 | 一种治疗肺鳞癌和小细胞肺癌的中药复合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102058744B (zh) | 一种治疗恶性肿瘤的中药组合物及其制备方法 | |
CN100428949C (zh) | 一种红豆杉抗癌中药制剂 | |
CN102114099B (zh) | 抑制肝癌的中药制剂及其制备方法 | |
CN102772523B (zh) | 用于肿瘤治疗的苦灵芝组合物及其制备方法 | |
CN102861193B (zh) | 一种治疗胃癌的中药组合物 | |
CN107468747A (zh) | 一种有利于抗癌、防癌的人参组合物及其制备方法 | |
CN102861284A (zh) | 一种治疗非小细胞肺癌的中药复方制剂及其制备方法 | |
CN103263587B (zh) | 一种治疗鼻咽癌放疗后毒副作用的中药制剂及制备方法 | |
CN105596890A (zh) | 一种制备治疗肺癌的中药组合物的方法 | |
CN103933450A (zh) | 一种预防或/和治疗胃肠疾病的中药组合物及其制备方法 | |
CN101564464B (zh) | 一种调节肿瘤患者机体免疫力的中药药物 | |
CN103550718B (zh) | 一种治疗肺癌的中药组合物 | |
CN101347543A (zh) | 一种中药组合物及其制备方法 | |
CN104189251A (zh) | 治疗乳腺增生、良性乳腺肿瘤的中药组合物及其制备方法 | |
CN101164558B (zh) | 一种化瘀止痛药物组合物及其制备方法与用途 | |
CN104027447B (zh) | 一种治疗癌症的中药 | |
CN108186794B (zh) | 一种治疗肺癌的中药组合物及其制备方法和应用 | |
CN102078352B (zh) | 一种治疗癌症的组合物 | |
CN102423384B (zh) | 一种治疗肺癌的中药制剂及其制备方法 | |
CN104258046A (zh) | 一种配合tp方案治疗中晚期非小细胞肺癌的中药组合物及其制备工艺 | |
CN103191267A (zh) | 一种治疗肝癌的中药组合物 | |
CN101693096A (zh) | 一种治疗肝癌的药物及其制备方法 | |
CN106334140A (zh) | 一种中药组合物及其制备方法 | |
CN101007114B (zh) | 一种肿瘤患者辅助用药品或保健品及其制备方法 | |
CN105412708A (zh) | 一种治疗肺癌的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160525 |